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Executive Summary
Despite consistent efforts of the government and national stakeholders, every year in Bangladesh over 5,000
mothers and thousands of children die. Most of these deaths are preventable and could be treated by
increased access to quality services including existing medicines and other health commodities. The United
Nation’s Commission on Life-Saving Commodities for Women and Children suggests that an important cause
of these deaths is lack of access and appropriate use of 13 life-saving commodities.
This document describes an effort by Population Council to assess the country’s policies, guidelines, and
availability for these 13 life-saving commodities as well as engaging with key stakeholders to implement the
UN Commission’s recommendations in conjunction with this assessment’s findings. This assessment validated
the availability of the 13 commodities in three districts at district, sub-district, and community levels, and
within drug stores, in in 15 government facilities and 27 private drug stores in August and September 2013.
Key stakeholders (including Ministry of Family Health and Welfare and government officials, members of
professional associations, and non-governmental representatives) were consulted. A national workshop
stimulated discussion, identified national priorities and information gaps, and identified areas requiring policy
review. This stakeholder engagement helped identify opportunities for their organizations’ contributions to
implementing the UN Commission recommendations.

FINDINGS
Regulatory issues
The assessment determined that Bangladesh has well-developed policies to regulate production, distribution,
sale, and use of all drugs as well as ensuring they are of good quality, efficacious, and safe. It is also revealed
that all drugs, medicines, and other mechanical substances in final dosage forms (those manufactured,
imported, distributed, marketed, or consumed in the country) must be registered with the regulatory authority—
the Directorate General of Drug Administration. The the registration must specify dosage form and strength,
according to the country’s Drug Control Committee (a committee of the Directorate General of Drug
Administration). The Directorate General of Drug Administration’s capacity seems to be logistically limited and
lacks skilled manpower, while other regulatory factors including pharmaceutical companies’ individual
operating procedures, quality control, and quality assurance programs complicate regulatory issues.

Registration and commodity availability
The assessment found that many policymakers and program managers are not aware of the UN Commission
report nor its recommendations. Stakeholders who were aware were generally from international and UN
organizations and involved in actual implementation of the Commission’s recommendations.
With the exception of the female condom, however, each of the 13 life-saving commodities is registered and
available in Bangladesh. Not all of maternal and neonatal commodities are registered in the dosage forms
recommended by the World Health Organization for their specified indications, nor do service delivery
guidelines provide indications for their use.
Availability and shortage need to be addressed. Oxytocin and Misoprostol were not available in two out of three
district hospitals visited but were available in all Mother and Child Welfare Centers. Similarly, Misoprostol was
not available in any Union Health and Family Welfare Centers or Community Clinics visited.
Although Oxytocin is available and used for induction of labor and preventing postpartum hemorrhage in most
district and sub-district facilities (although not in community facilities), consistent lack of cold chain storage
necessary for the drug’s integrity remains a significant challenge. Many government facilities and most private
drug stores lack functioning refrigerators. Often Oxytocin is stored on an open shelf, rendering it ineffective.
1

Misoprostol is registered in Bangladesh and, in recent years, was introduced and scaled up for postpartum
hemorrhage prevention and management at the community level. Service Delivery Guidelines are available for
community use. Thus far, 19 out of 64 districts have the Guidelines. Discussions are ongoing to bundle
Misoprostol with safe delivery kits.
Magnesium sulphate is registered for prevention and treatment of severe pre-eclampsia and eclampsia, but it
was not available in one out of two Mother and Child Welfare Centers and two out of five Upazila Health
Complexes visited. Service delivery guidelines are available for community service providers. Community
service providers tend to prefer single dose solutions for intramuscular injection in a pilot study underway in
two sub-districts and upazilas, rather than other dosages or formulations. Population Council is currently
conducting a study to determine whether it is feasible and acceptable for community service providers to
administer an intramuscular loading dose of magnesium sulfate before referral.
Several injectable antibiotics, including those recommended by the United Nations Commission, including
amoxicillin for treatment of pneumonia, are registered and available in various dosage forms for treating
neonatal sepsis and other infectious conditions. Injectable antibiotics were not available in one out of three
District Hospitals, no Mother and Child Welfare Centers, nor two out of five Upazila Health Complexes.
Chlorhexidine is registered and available in various dosage forms but not in the concentration necessary for
neonatal cord care. Chlorhexidine 7.1% is not included in the country’s Essential Drug List or Dietary and Drug
Supply Kits, and no Service Delivery Guidelines are available. Although the antenatal corticosteroids
dexamethasone and betamethasone are registered and available in the country in various dosage forms, the
available dosage forms are not suitable for pre-term respiratory distress syndrome and are not included in the
Essential Drug List, and no Service Delivery Guidelines are available.
Encouragingly, the National Core Committeef for Neonatal Health of the Directorate General of Health Services
and the Directorate General of Family Planning’s National Technical Committee have approved piloting and
scale up in one district of the required dose of dexamethasone for pre-term respiratory distress syndrome and
Chlorhexidine 7.1% for neonatal cord care. Service Delivery Guidelines are being prepared.
Oral rehydration salts and zinc are widely available as over-the-counter products and are used for diarrhea.
Both are included in the Essential Drug List, and Service Delivery Guidelines are available.
Resuscitation devices for newborn asphyxia have been distributed to 19 districts. The devices were available in
two out of three District Hospitals, one out of two Mother and Child Welfare Centers, three out of five Upazila
Health Complexes, two out of four Union Health and Family Welfare Centres, and no Community Clinics visited.
Resuscitation devices for newborn asphyxia were not found in any private drug stores.
Two types of contraceptive implants are registered. A single rod implant (Implanon) is registered and used in
the government program, while a two rod implant, Jadelle (as I-plant), is registered and marketed in the private
sector through Social Marketing Company. These are included in the country’s approved contraceptive
methods and Service Delivery Guidelines are widely available. Although there is no domestic manufacturing of
implants, there were no supply shortages of implants in the facilities visited.
Emergency Contraceptive Pills are registered and have been used in Bangladesh for the last decade as an
over-the-counter product, free of cost in the government program. Supplies are obtained from four domestic
pharmaceutical companies, as well as imports, yet actual supplies in facilities are inconsistent. Although
Emergency Contraceptive Pills were available in private drug stores, the drug was unavailable in government
facilities.
The female condom is not registered in Bangladesh, as policymakers and program managers consider it
unsuitable for the local context.
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Challenges Identified
• Shortages of all essential drugs and commodities in public health facilities;
• Inappropriate storage of oxytocin (and subsequent use of an ineffective drug during crucial medical events)
is widespread;
• Unavailability of antenatal corticosteroids in correct dosage forms (6 mg injection) for pre-term respiratory
distress syndrome; unavailability of Chlorhexidine in the correct concentration (7.1%) for newborn cord care;
provider use of inappropriate concentration; and lack of related Service Delivery Guidelines;
• Unavailability of magnesium sulfate in appropriate dose forms; manufacture of a single loading dose for
severe pre-eclampsia and eclampsia is needed, but pharmaceutical companies lack interest;
• Lack of advocacy with pharmaceutical companies for manufacturing less profitable but essential drugs in
appropriate dosage forms;
• Lack of awareness of Emergency Contraceptive Pills due to lack of educational efforts;
• Lack of knowledge and low use of zinc sulphate for neonatal diarrhea;
• Absence of a Directorate General of Family Planning forum for advocating for mothers and ensuring access
to and use of essential maternal health drugs and commodities.

Opportunities Identified
• All 13 life-saving drugs and commodities are registered (except female condom) in the country in different
dosage forms, which means that additional, altered dosage forms is feasible.
• The Directorate General of Drug Administration is very much in favor of ensuring the availability, quality, and
affordability of essential maternal and neonatal health drugs and commodities. The Directorate requested
an application for the approval of essential drugs in required dose forms. The Directorate General of Family
Planning was requested to form an advocacy forum to ensure availability of maternal health drug and
commodities, and Systems for Improved Access to Pharmaceuticals and Services supported a Forecasting
Working Group in the Directorate. The Directorate General of Health Services has a Supply Chain
Coordination Forum that coordinates with the United Nations, World Bank, the Joint United Nations
Programme on HIV/AIDS, the Ministry of Family Health and Welfare, and other stakeholders.
• Chlorhexidine has already been approved by the Directorate General of Drug Administration in the
appropriate concentration, and the National Core Committee for Neonatal Health of the Directorate General
of Health Services and the Directorate General of Family Planning’s National Technical Committee have
approved its use in the vertical program. Social Marketing Company has reportedly begun manufacturing the
drug, and Save the Children is piloting product use in one district.
• The National Core Committee for Neonatal Health of the Directorate General of Health Services and the
Directorate General of Family Planning’s National Technical Committee have approved the introduction and
scale up of dexamethasone sodium sulphate 6 mg intramuscular injection for pre-term respiratory distress
syndrome for both facilities and use within communities.
• The Directorate General of Drug Administration has issued a letter for the appropriate storage of oxytocin in
all public health facilities. The Directorates General of Health Services and Family Planning have also issued
guidance to all facilities.
• Systems for Improved Access to Pharmaceuticals and Services and other stakeholders are facilitating both
the Directorate General of Health Services’ and the Directorate General of Family Planning’s quantification of
maternal and neonatal commodities needed for the facility level. The Directorate General of Family Planning
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has a logistics managment and information system for tracking the 13 recommended commodities, and they
have also proposed including Chlorhexidine and misoprostol in standard infant delivery kits.
• Participating respondents are concerned about the unavailability and inappropriate dosage forms of
maternal and neonatal commodities, which suggests a wide basis of support for improved commodity
availability.
• Participating respondents are concerned about the use of low dose misoprostol for postpartum hemorrhage
prevention and treatment.
• Social Marketing Company and EngenderHealth’s Mayer Hashi program have initiated training to insert and
remove implants through private providers.

Recommendations
For Maternal Health
• Misoprostol should be bundled with birthing delivery kits.
• Manufacture of a single loading dose of the magnesium sulfate solution should be consistently advocated
for with pharmaceutical companies.
• Stakeholders suggest an assessment of the effectiveness of 400 mcg versus 600 mcg misoprostol for
preventing postpartum hemorrhage among Bangladeshi women.
• Essential drugs and commodities for mothers should be made available at Union Health and Family Welfare
Centres where normal vaginal deliveries are planned and conducted.
For Neonatal Health
• Chlorhexidine should be bundled with birthing delivery kits.
• Resuscitation devices should be available in all districts, particularly in all facilities where deliveries are
conducted.
• Advocacy should be conducted with pharmaceutical companies for manufacture of a single dose of
gentamycin injection and 7.1% Chlorhexidine.
• Essential drugs and commodities for neonates should be made available in Union Health and Family Welfare
Centres, where normal vaginal deliveries are planned and conducted.
• Single doses of injectable antibiotics should be manufactured and promoted for neonatal sepsis.
• Educational efforts should be strengthened for increasing awareness of zinc use in diarrheal diseases.
For Family Planning Commodities
• The Directorate General of Family Planning should increase public awareness how to avoid unplanned
pregnancies and ensure availability of Emergency Contraception, including provision for field workers.
General recommendations
• A forum at the Directorate General of Family Planning should be formed to advocate for ensuring access to
and use of maternal and newborn drugs and commodities.
• Further initiatives are necessary for ensuring drug quality, dosage appropriateness, and reliable availability in
both the private and public sectors.
• The Directorates General of Drug Administration, Family Planning, and Health Services should be regularly
updated by active stakeholders on global updates in maternal and neonatal health and other public health
issues.
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Background
The United Nations (UN) Secretary General’s Global Strategy for Women’s and Children’s Health 2010 report
highlighted the lack of access to life-saving commodities resulting in preventable deaths of women and
children. The Strategy called on the global community to work together to save 16 million lives by 2015
through increasing access to and appropriate use of essential medicines, medical devices and health supplies
during pregnancy, childbirth, the postnatal period, and childhood.
The UN secretary General convened the UN Commission on Life-Saving Commodities for Women and Children
(the Commission), which is a part of the Every Woman, Every Child movement, with the overall goal of
increasing access to life-saving commodities in 50 of the world’s poorest countries. The Commission identified
and endorsed an initial list of 13 overlooked life-saving commodities that, if more widely accessed and properly
used, could save the lives of more than six million women, newborns, and children, including prevention of 1.8
million child deaths annually and 230,000 maternal deaths, through increased access to family planning (FP)
around the world. The 13 commodities identified include oxytocin and misoprostol for postpartum hemorrhage
(PPH), Magnesium sulphate (MgSO4) for severe pre-eclampsia and eclampsia, injectable antibiotics for
newborn sepsis, Antenatal corticosteroids (ANCS) for pre-term respiratory distress syndrome, chlorhexidine for
newborn cord care, resuscitation devices for newborn asphyxia, amoxicillin for pneumonia, oral rehydration
salts (ORS) and zinc for diarrhea; and female condoms, contraceptive implants, and emergency ontraceptive
pills (ECPs) for contraception.
The Commission also identified key interrelated barriers that prevent access to and use of the 13
commodities, which severely under-resourced regulatory agencies in low-income countries, leading to delayed
registration of commodities; lack of oversight of product quality and general inefficiencies; market failures,
where return on investment is too low for encouraging manufacturers to enter the market or produce sufficient
quantities; and user supply and demand challenges such as limited demand for the product by end users, local
delivery problems, and incorrect prescription and use. To address these challenges and deliver on the promise
of saving the lives of millions of women, newborns, and children, the Commission recommended ten actions to
be achieved within definite preriods of time. These actions focus on the need for improving global and local
markets for life-saving commodities, innovative financing, quality strengthening and regulatory efficiency,
improved national commodity delivery, and better integration of private sector and consumer needs.
In Bangladesh, 12 of the 13 commodities are registered (except female condoms), but the extent to which
these commodities are available at point of presacription and use, their doses and forms, policies for use,
client access, and awareness are not widely, particularly at the district level. Furthermore, little is known about
health workers’ knowledge and technical competencies. Bangladesh’s Ministry of Health and Family Welfare
(MoHFW) comprises two divisions: the Directorate General of Health Services (DGHS), responsible for ensuring
availability of maternal child health drugs, supplements, and devices; and the Directorate General of Family
Planning (DGFP), which is responsible for ensuring contraceptive availability. DGFP is also responsible for
ensuring availability of maternal child health drugs, supplements, and devices, in addition to contraceptives, at
health facilities. The Directorate General of Drug Administration (DGDA) under MoHFW is the country’s Drug
Regulatory Authority.
Globally, efforts are underway to implement the UN Commission recommendations on Life-Saving Commodities
for Women and Children. In an effort to contribute to the Government of Bangladesh’s implementation plan for
these recommendations, Population Council, with support from the Hewlett Foundation, assessed the
availability of the 13 life-saving commodities to provide empirical information for decision making within the
country’s health sector.
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Objective
This assessment’s primary objective was to examine the policies, guidelines, and availability for the 13
identified life-saving commodities in Bangladesh as well as engaging with policymakers and program managers
in implementing the UN Commission recommendations in light of the assessment’s findings. This
assessment’s findings are expected to be used as to stimulate discussion, identify national priorities and
information gaps, influence policy formulation, and increase access to the commodities and assist
international advocates for global advocacy. The specific objectives of this exercise are to:


Engage with national leaders on determining national priorities and information gaps about the 13 maternal
and neonatal health products;



Examine policies and guidelines of the 13 life-saving commodities;



Explore procurement mechanisms of the 13 life-saving commodities/supplies;



Explore manufacturing capacity, availability of quality assurance guidelines and policies, product packaging
policies, distribution mechanisms, cost to end users and financing;



Examine access to and availability of the 13 life-saving commodities at public sector facilities at district, subdistrict, and community levels, as well as at private drug stores;



Assess stakeholders’ and professional associations’ interest and participation in ensuring commodity
supplies; and



Stimulate discussion among decision makers and help identify policy options for increasing commodity
access and availability.
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Methodology
This Maternal Health Commodity Landscaping Exercise comprised two activities: assessing and providing a
comprehensive description of maternal and neonatal health (MNH) commodity issues, from policy formulation
to point of care; and engaging stakeholders for implementing the UN Commission recommendations. The
study’s methodology included a document review of the policies, service guidelines, and availability and use of
the 13 life-saving commodities as well as validating the availability of those commodities in district, subdistricts, and community facilities and private drug stores. Stakeholders provided recommendations regarding
the areas of assessment along with susequent discussion of the results and identification of priority actions.

NATIONAL ASSESSMENT
Document review of policies, guidelines,
and use of 13 life-saving commodities
Policy documents, policies, service delivery guidelines and
circulars were collected and reviewed, complemented by
searches for drug manufacturers at www.bddrugs.com
and pharmaceutical companies’ web sites, as well as
www.dgda.gov.bd, the Directorate General of Drug
Administration’s web site (Appendix 1). These document
reviews and searches were further complemented by 21
in-depth interviews with representatives from MoHFW,
professional associations and bodies, development
partners, pharmaceutical companies, and NGOs, for
clarification and greater detail about the drug and
commodity landscape in Bangladesh. The findings from
these searches and interviews combined to described the
availability of the 13 recommended commodities, as well
as related policy gaps, existing procurement mechanisms,
manufacturing capacity, quality assurance guidelines and
policies including product packaging, distribution and
logistics, costs for end users, and financing. These
activities provided mechanisms for engaging national and
regional stakeholders and professional associations in
ensuring supplies, identifying national priorities, and
information gaps.

Availability of the 13 life-saving commodities

DOCUMENTS REVIEWED
• Drug Policy of the Government
of Bangladesh, MoH&FW
• Quality Manual of Directorate General
of Drug Administration, Bangladesh,
MoH&FW
• DGHS and DGFP operation plan 2011-2016,
MoH&FW
• “Training Manual of Use of Misoprostol
to Prevent Postpartum Hemorrhage (PPH),”
MoH&FW, USAID, EngenderHealth.
• “Information Kit on Use of Misoprostol
to Prevent PPH at Home Delivery,” MoH&FW
and EngenderHealth
• “National Protocol for Providing Loading Dose
of Magnesium Sulphate (MgSO4)
by the Community Level Service Providers,”
MoH&FW, Obstetrical and Gynecological
Society of Bangladesh (OGSB),
EngenderHealth, Maternal and Child Health
Integrated Program (MCHIP), and
Population Council
• “Family Planning Manual,” Directorate
General of Family Planning (DGFP), MoH&FW
• Trainer’s Handbook, “Active Management
of Third Stage of Labor,” MoH&FW
• Minutes of National Core Committee,
Neonatal Health (NCC-NH), MoH&FW
• Minutes of National Technical Committee
(NTC), DGFP
• Revised supply manual (2013), DGFP

District, sub-district and community public facilities as
well as private drug stores were visited to determine if the
13 recommended commodities were available. Public
drug stores were also visited to assess commodity
availability, stock outs, and drug storage (including humidity and temperature control and refrigeration). A
checklist was used to collect this information. Fifteen government facilities from three districts were visited
including three District Hospitals, two Maternal and Child Welfare Centers (MCWCs), five Upazila Health
Complexes (UHCs), four Union Health and Family Welfare Centers (UH&FWCs), and one Community Clinic (CC).
Twenty-seven private drug stores were visited for information on drug availability, indications for which they are
sold, and price; 16 of the 27 drug stores were at the district level and 11 were at the sub-district level.
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STAKEHOLDER ENGAGEMENT
A half day national workshop on 8 October 2013 in Dhaka with 22 policymakers, program managers,
regulators, pharmaceutical industry representatives, and other stakeholders shared and discussed the findings
of the assessment and identified priority activities for implementing the UN Commission’s recommendations
within the Bangladeshi context.
In addition to Population Council’s presentation, two other organizations presentated information on maternal
and neonatal health commodity issues.
The sessions enabled the Council to engage with DGFP, DGHS, and other stakeholders, to sensitize them to
the Commission’s recommendations and exploring their introduction in Bangladesh, as well as providing an
opportunity for developing recommendations that emerged from the workshop and discussing them.

Workshop participants
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Results
The findings of this report triangulate the results from the review of policy documents, in-depth interviews, at
facility and drug store validation assessments, the validation workshop, and findings from the efforts to
engage policy makers, program managers, and other stakeholders in implementation of the UN Commission
recommendations.

NATIONAL DRUG POLICY
Drug policies and guidelines
The Directorate General of Drug Administration (DGDA), a
division of MoHFW, is Bangladesh’s Drug Regulatory Authority.
Interviews with DGDA officials revealed that it controls and
regulates production, distribution, sale, and use of any drugs in
the country. DGDA’s primary responsibility is to ensure that drugs
are safe, efficacious, and of good quality. The National Drug
Policy was formulated in 1982, and currently the Drugs Act 1940
(XXIII of 1940) and Drugs (control) Ordinance 1982 (VIII of 1982)
regulates registration, manufacturing, distribution, sale,
importation, and exportation of any drugs in Bangladesh.
Oxytocin supply at a facility

All drugs, medicines, and other mechanical substances in final
dosage forms manufactured, imported, distributed, marketed, or consumed in Bangladesh must be
registered with DGDA for the specific dosage form and strength recommended by the Drug Control
Committee (of DGDA). An important objective of the National Drug Policy is to make good quality drugs
available at affordable prices, and therefore the policy requires quality assurance at different stages—
manufacturing, transit, and storage, with testing at different times before it reaches the end user.
Interviews with policy makers and program mangers suggest that those responsible for implementing
maternal health policies and services were not aware of the specifics of maternal health commodity policies
and the UN Commission report and its recommendations. A few stakeholders, particularly the international
development organizations and UN agencies, are aware of UN Commissions’ recommendations.

Drug registration, indications, dose forms and presentations, and essential drugs list
All 13 life-saving commodities are registered in Bangladesh with the exception of female condoms. Some of
the commodities are not registered in the specific dose forms needed for particular MNH conditions or
indications. A feasibility and acceptability study of the female condom by Social Marketing Company
produced results that were not compelling enough to merit its introduction; policymakers and program
managers suggested that the female condom would not have substantial uptake in Bangladesh.
Oxytocin and magnesium sulphate are reported as registered and in
use throughout the country for a long time. Oxytocin is registered for
induction of labor and PPH prevention and treatment, available in 5
iu/1ml ampoules, for both IM and IV injections, and in tablet form.
Only one pharmaceutical company manufactures oxytocin tablet, and
it is perceived as less effective than injection for the same indications.
Service delivery guidelines (SDGs) for oxytocin are in place and
followed in all facilities.
Magnesium sulphate (MgSO4) is registered for prevention and
treatment of severe pre-eclampsia (SPE) and eclampsia and is
Oxytocin tablets
available at 49.3% w/v in 5 ml ampule (2.46 gm) and 4% w/v in 16.4
mmol or 4.0 gm/100 ml solution for injection and infusion (IV/IM) forms (Table 3a and Table 3b). Although
MgSO4 is registered and used for preventing and treating SPE and eclampsia, it is not available for this
9

indication as a single loading dose (10 mg IV/IM) at the community level. Two studies, at the request of the
National Technical Committee, are operationalizing and assessing the ability of community service providers
to detect, prevent, and treat SPE and eclampsia with a single loading dose of MgSO4 before referral.
Magnesium sulfate SDGs, for use by providers in community facilities, have been developed by MoHFW, the
Obstetrical and Gynecological Society of Bangladesh, EngenderHealth, and Save the Children, and are being
tested1.
Misoprostol is registered, in two tablet dose forms (100 mcg, and 200 mcg), for gastrointestinal indications.
Recently manufacturers’ brochures have included indications such as labor induction, PPH prevention and
treatment, abortion induction, abortion incompletion, miscarriage, postabortion care, and intrauterine fetal
death for which cervical ripening or softening is required.
Although WHO, FIGO, and other professional bodies have recommended 600 mcg of Misoprostol for PPH
prevention and management, the dosage approved by the National Technical Committee is 400 mcg. The
National PPH Prevention Task Force and other relevant stakeholders recommended the lower dose based on
Bangaldeshi women’s shorter stature and lower weight, but whether 400 mcg effectively prevents or treats
PPH has not been evaluated. Anecdotal evidence suggests the 400 mcg dosage is ineffective, meriting its reevaluation. Single 400 mcg doses are available in individual packages for PPH prevention and treatment.
Misoprostol 400 mcg is being scaled up in phases in another 18 districts. DGFP has included procurement
(1.8 million pills or the equivalent of 0.9 million doses have already purchased) and distribution of
Misoprostol in its operational plan (OP), and SDGs are available2, and Misoprostol tablets are now included
in the country’s Essential Drug List (Appendix 2).
As in other developing countries, fatality rates for severe bacterial infections in neonates (neonatal sepsis)
are high in Bangladesh, partially due to the unavailability, or late or inadequate administration, of necessary
antibiotics3,4. The UN Commission identified the three (procaine benzyl penicillin, gentamicin sulphate,
ceftriaxone) most cost-effective antibiotics for neonatal sepsis. WHO recommends antibiotic treatment with
procaine benzyl penicillin and gentamicin as initial therapy for presumptive treatment in newborns at risk of
bacterial infection5. WHO recommends intramuscular injections (IM) of 50 mg/kg body weight of ampicillin
(or a comparable penicillin such as procaine benzyl penicillin) every six to eight hours, depending on age,
plus 7.5 mg/kg body weight of gentamicin (or another comparable aminoglycoside), divided twice daily for at
least 10 days, as the standard therapy 6. WHO also recommends, as a secondary therapy, daily injection of a
single dose of ceftriaxone7 alone, of 50 mg/kg body weight for all newborns except those older than one
week and weighing more than two kgs. In those slightly older and heavier newborns, the daily dose is
increased to 75 mg/kg for 10 days.8
In Bangladesh amoxicillin is available in many forms—powder for suspension, drops, tablet and injection—for
pneumonia treatment. Procaine benzyl penicillin, gentamicin sulphate, ceftriaxone, and amoxicillin are each
registered and indicated for newborn sepsis and other life-threatening infections. Procaine benzyl penicillin,
gentamicin sulphate, and amoxicillin are listed in the EDL, but ceftriaxone is not (Appendix 2). The available
doses for procaine benzyl penicillin are procaine penicillin 3 lac and benzyl penicillin 1 lac/vial for IM
injection; 20 mg and 80 mg of gentamycin sulphate for IM/IV injection and 250, 500, 1,000, and 2,000 mg
of ceftriaxone for IM/IV injection. Amoxicillin is available in the dose forms of 100 mg/1ml drop, 125 mg/5
ml suspension, 250/500 mg/vial IM/IV injection and 250 mg/tablet dispersible tablet. SDGs are available
1
2
3

4

5
6

7
8

MoHFW, OGSB, Save the Children (MaMoni project), and EngenderHealth. 2011. Guideline for prevention and management of pre-eclampsia
and eclampsia at the Community. Guideline for community level service providers. EngenderHealth: Dhaka.
MoHFW, EngenderHealth, Bangladesh and The National PPH Prevention Task Force. 2009. Guideline on Misoprostol Use in Bangladesh to
prevent PPH at the Community level. EngenderHealth: Dhaka.
Thaver D, Zaidi AK. Burden of neonatal infections in developing countries: a review of evidence from community-based studies. Pediatric
Infectious Disease Journal. 2009;28(S1):S3–S9.
Neonatal sepsis web page. Merck Manual website. Available at:
www.merckmanuals.com/professional/pediatrics/infections_in_neonates/neonatal_sepsis.html#v1092175.
Procaine benzyl penicillin is not recommended as first‐line treatment for neonatal sepsis except in settings with high neonatal mortality,
when given by trained health workers in cases where hospital care is not achievable.
WHO. Management of the Child With a Serious Infection or Severe Malnutrition: Guidelines for Care at First Referral Level in Developing
Countries. Geneva: WHO; 2000: 62.
WHO recommends not to administer with calcium and avoid in infants with hyper-bilirubinemia.
Saez-Llorens X, McCracken GH. Clinical pharmacology of antibacterial agents. In: Remington JS, Klein JO, eds. Infectious Diseases of the
Fetus and Newborn Infant. Philadelphia: W.B. Saunders Company; 2001: 1419–1466.
10

for all four drugs. During the sixth meeting of DGHS’s National Core Committee for Neonatal Health (NCC-NH)
(2 September 2013) including dispersible amoxicillin tablet in the EDL was suggested9. Similarly, DGFP’s
61st National Technical Committee (26 November 2013) approved amoxicillin dispersible tablets for the
Dietary and Drug Supply (DDS) Kit 10 of primary health and FP facilities for treating neonatal sepsis.
For women at risk of pre-term delivery within seven days, WHO recommends a single course of
corticosteroids between 24 weeks and 34 weeks of gestation.11 A single course of antenatal corticosteroids
(ANCS) should be administered to women with premature rupture membranes before 32 weeks of gestation
to reduce risk of pre-term respiratory distress syndrome (PTRDS), perinatal mortalities, and other morbidities.
Dexamethasone sodium phosphate and betamethasone sodium phosphate are the two ANCS’s
recommended for accelerating fetal lung development in threatened pre-term birth. WHO, NIH, ACOG, RCOG,
and WAPM list both as effective drugs for preventing complications of prematurity, using either a dosage of
24 mg of dexamethasone IM injection (4 doses of 6 mg 12 hours apart) or 24 mg of betamethasone IM
injection (2 doses of 12 mg 24 hours apart) 12,13. As of April 2013, the 18th edition of the WHO Model List of
Essential Medicines, which for the first time includes antenatal corticosteroids, lists only dexamethasone
sodium phosphate for fetal indications14.
The ingredients for antenatal corticosteroids (dexamethasone sodium phosphate and betamethasone
sodium phosphate) are registered in Bangladesh in different dose forms and for various indications, but not
for pre-term respiratory distress syndrome (Table 3a and Table 3b). SDGs for the other indications are
available, but not for pre-term respiratory distress syndrome. Dexamethasone sodium phosphate and
betamethasone sodium phosphate are registered as 0.5 mg tablet, 0.1% eye drop, 0.05% eye ointment, and
5 mg injection (only dexamethasone) dose forms for various indications, but not in 6 mg dose form as
injection, which is indicated for pre-term respiratory distress syndrome. Although dexamethasone and
betamethasone are listed in the EDL, 6 mg dose is not. DGHS’s sixth National Core Committee for Neonatal
Health meeting approved introduction and scale up of 6 mg IM injection of dexamethasone for pre-term
respiratory distress syndrome at the facility and community levels 15. Pilot testing is ongoing in one district for
assessing the feasibility and efficacy of ANCS in pre-term respiratory distress syndrome. Save the Children is
working with DGHS, DGFP, and pharmaceutical companies to make the available dose form and include
SDGs.
Chlorhexidine digluconate, a broad spectrum antiseptic, is commonly used worldwide for various indications.
WHO added 7.1% Chlorhexidine digluconate (delivering 4% Chlorhexidine) to the 2013 Model List of
Essential Medicines for Children under Specific Medicines for Neonatal Care (Section 29) for neonatal cord
care. Chlorhexidine cord cleansing (7.1% chlorhexidine digluconate) should not to be confused with other
Chlorhexidine interventions using Chlorhexidine gluconate, such as solution for vaginal cleansing (0.16%–
0.60%), neonatal skin wiping (0.16%–0.60%), eyewash (0.05%), dental wash (0.12%), or preoperative skin
cleansing (2.0%).
Chlorhexidine gluconate is registered in different dose forms for various indications in Bangladesh, but not
for newborn cord care; it is listed in the EDL for the other indications (Appendix 2), with SDGs available.
Although they are not effective for cord care, the available dose concentrations are widely used in
Bangladesh for newborn cord cleansing. The appropriate dose form (7.1%, according to WHO) for cord
cleansing has been shown to be highly effective in the region: Three community-based randomized control
trials in Nepal, Bangladesh, and Pakistan resulted in Chlorhexidine cord cleansing’s substantial reduction of
neonatal mortality in all three countries, by 24 percent in Nepal, 20 percent in Bangladesh, and 38 percent

9
10
11

12

13
14
15

DGHS, MoHFW.2013. Minutes of the 6th meetings of the National Core Committee for Neonatal Health. Dhaka: DHGS.
DDS Kit is a box containing 26 pre-selected essential drugs, and dietary items to be dispensed by the community-based facility level service
providers at UH&FWCs for patient management. Each month they receive certain number of DDS Kits from the central warehouse.
Threatened pre-term birth can be characterized by four signs and symptoms that include i) fluid leaking from vagina (rupture membrane); ii)
painful uterine contractions; iii) antepartum haemorrhage (vaginal bleeding); and iv) signs and symptoms of severe pre-eclampsia and
eclampsia.
WAPM: Guideline for the use of antenatal corticosteroids for fetal maturation (2008). (Xavier Miracle1, Gian Carlo Di Renzo, Ann Stark,
Avroy Fanaroff, Xavier Carbonell- Estrany1 and Erich Saling. J. Perinat. Med. 36 (2008). New York.)
Cochrane summary: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth.
WHO Model List of Essential Medicines, 18th list (April 2013).
DGHS, MoHFW.2013. Minutes of the 6th meetings of the National Core Committee for Neonatal Health. Dhaka: DHGS.
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in Pakistan. Chlorhexidine cord cleansing also reduced severe cord infection by 75 percent in Nepal, 65
percent in Bangladesh, and 42 percent in Pakistan.
DGHS’s sixth National Core Committee for Neonatal Health meeting, prior to the stakeholder meeting, was a
turning point, at which application to all newborn umbilical stumps at birth16 of 7.1% aqueous solution of
Clorhexidine gluconate, regardless of place of birth (home or facility), was approved and listed as part of the
essential neonatal care (ENC) package. The committee also suggested including 7.1% Chlorhexidine in the
EDL. Similarly, DGFP’s 61st National Technical Committee meeting approved Chlorhexidine 7.1% aqueous
solution’s inclusion in primary health and FP care facilities’ Dietary and Drug Supply (DDS) Kits for newborn
cord care. Save the Children is scaling it up in one district, and SDGs are being prepared. Dialogue is being
initiated with reputed pharmaceutical companies to encourage the production and marketing of aqueous
solution of 7.1% Chlorhexidine nationwide.17
Almost half of all newborn deaths occur within the first 24 hours, with most resulting from birth asphyxia due
to intra-partum complications. This condition, manifesting as newborn failure to establish breathing after
birth, is responsible for one quarter of all newborn deaths worldwide each year18. Many of these deaths
could be easily prevented with basic neonatal resuscitation, which requires tactile stimulation, a neonatal
bag and mask, suction device, and a resuscitation training mannequin. With this basic equipment and
effective pre- and in service training, successful resuscitation of newborns is possible for about 30 percent of
cases otherwise resulting in death among full term babies, and for five to ten percent of pre-term births19.
The WHO Essential Medical Devices List, which is currently being
updated for priority interventions for Maternal, Neonatal and Child
Health, includes neonatal resuscitators (self-inflated bag and mask),
suction devices, and resuscitation training mannequins. The
resuscitation device is registered in Bangladesh, but there is no
Essential Medical Devices List in Bangladesh. The device has been
donated by USAID in selected districts under the Helping Babies
Breathe (HBB) program implemented by DGHS, ICDDR,B, and Save
the Children, with technical assistance from UNICEF. SDGs are
available.
Oral Rehydration Salts (ORS),
introduced in Bangladesh by
ICDDR,B, are widely available
and in use. ORS is registered
Resuscitation device
and incorporated into the EDL
for diarrheal treatment of children, with SDGs. ORS is over-the-counter,
has a strong safety profile, and has no cold chain storage requirements.
The standard treatment guidelines for diarrhea in Bangladesh follow the
WHO-UNICEF Integrated Management of Childhood Illnesses (IMCI)
guidelines. Recently, zinc sulphate monohydrate was added for diarrhea
management as an adjunct therapy, as it has proven effective in
Service Delivery Guideline
reducing diarrheal episodes, as well as their duration. Zinc is registered
on resuscitation device
in Bangladesh, listed in the EDL, with SDGs available. ORS in
Bangladesh is available in various forms mixed with nutritional components (under brand names such as
ORSaline-N, ORSaline Fruiti, Tasti Saline), while zinc sulphate monohydrate is available in tablet and syrup, a
10/20 mg/tablet or 5 ml syrup. New WHO and UNICEF formulations of ORS have Sodium Chloride 1.30 gm,
Potassium Chloride 0.75 gm, TriSodium Citrate/Dye Hydrate 1.45 gm, and Glucose/Anhydrous 6.75 gm.

16
17
18
19

Guidelines suggest single application of 7.1% Chlorhexidine aqueous solution followed by dry cord care.
DGHS, MoHFW.2013. Minutes of the 6th meetings of the National Core Committee for Neonatal Health. Dhaka: DHGS.
Black, R., S. Cousens, H.L. Johnson, et al. 2010. Global, regional, and national causes of child mortality in 2008: a systematic analysis.
Lancet 375(9730): 1969–1987.
Wall, S.N. et al. 2009. Neonatal resuscitation in low resource settings: what, who, and how to overcome challenges to scale up. International
Journal of Gynecology and Obstetrics 107: S47-S64.
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The female condom is not registered in Bangladesh, and policy makers and program managers believe its
acceptance and use would not be significant. Contraceptive implants and emergency contraceptive pills
(ECPs) are, however, registered and included in DGFP’s contraceptive method mix. SDGs for these methods
are available. Two types of contraceptive implants are available: a three year single rod implant with 68 mg
etonogestrel, and a five year two rod implant, each containing 75 mg levonorgestrel.
In Bangladesh ECPs are an over-the-counter product manufactured by several
pharmaceutical companies in the country. DGFP’s 61st National Technical
Committee meeting in August 2013 approved a single dose (1.5 mg) ECP
regimen, instead of a two dose regimen of 0.75 mg/dose 12 hours apart, with
the period of time during which women can effectively take ECPs increased to
from 72 hours to 120 hours after unprotected sex. Although the drug is not listed
in the EDL or in the Dietary and Drug Supply Kits for primary health care facilities,
SDGs are available.
Emergency
Contraception Pill

DRUG AVAILABILITY
Government facilities and drug stores
A team visited 15 public sector facilities between August and
September 2013. In-depth interviews with policy makers,
program managers, and other stakeholders revealed that the
13 commodities, with the exception of female condoms, can
generally be found at health facilities at district, sub-district,
and primary care levels. Some drugs are not available in
WHO recommended doses for maternal and neonatal
indications, and drugs were not available on the day of the
visit at some facilities, and shortages were reported.
TABLE 1: Maternal and neonatal health drugs and commodities available in government facilities, by facility type
Maternal and neonatal
drug or commodity
Oxytocin
Misoprostol
Magnesium sulphate
Injectable antibiotics
Antenatal corticosteroid
Chlorhexidine
Resuscitation device
Amoxicillin
ORS
Zinc
Female condom
Contraceptive implants
Emergency contraceptive pill
N

Number of facilities, by type
DH
1
1
3
2
0
0
2
3
3
3
224
0
3

District
MCWC
2
2
1
0
0
0
1
2
0
1
2
0
2

Sub-district
UHC
4
3
2
3
0
0
3
4
4
2
3
0
5

Community
UH&FWC
CC
020
021
122
0
023
021
020
021
020
021
0
0
2
020
4
1
1
1
1
1
126
020
0
0
4

Total (%)

1

‘0’=Not available; ‘---‘=Never introduced; DH=District hospital; MCWC=Mother and Child Welfare Center;
UHC=Upazila Health Complex; UH&FWC=Union Health and Family Welfare Center, CC=Community Clinic

According to MoHFW policy, these centers are not allowed to provide this drug.
Service providers at this level are not allowed to administer any injectable antibiotic.
22 Misoprostol is in the process of scaling up with only 10 districts with community distribution thus far.
23 Loading dose is approved to provide from these centers and piloting is continuing.
24 These centers can provide these services only when they are designated or upgraded to provide the services.
13
20
21

7 (47%)
7 (47%)
6 (40%)
5 (33%)
0 (0%)
0 (0%)
8 (53%)
14 (93%)
9 (60%)
8 (53%)
8 (53%)
0 (0%)
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Corticosteroids (dexamethasone sodium sulphate and betamethasone sodium sulphate) and Chlorhexidine
were not found in MCWCs, UH&FWCs, and CCs. Where they were available, they were not in the right dose
forms for pre-term respiratory distress syndrome or newborn cord care. Resuscitation devices were available
in all facilities where health professionals and workers were trained under Helping Babies Breathe (see
Table 1) in 19 districts.
Antibiotic injections (amoxicillin) in different dose forms were found in most facilities, except one UHC, and
no MCWCs. (Availability of ORS, zinc sulphate, and contraceptive implants are presented in Table 1.) ECPs
were not available in any facilities due to supply shortages. Although some UH&FWCs are ready to provide
normal delivery services, they do not have any drugs except those in the DDS Kit (Appendix 3) such as
Chlorhexidine, misoprostol, oxytocin, and MgSO4 (Table 1).
Discussions with facility managers, service providers, and store keepers
revealed that SDGs for some of the 13 commodities are lacking and
providers depend on the materials provided by pharmaceutical companies.
No facility received any SDG from national authorities, and providers must
rely on their training and other resource materials. Providers indicated that,
since their initial training on these commodities, they were able to dispense
and administer them. Nurses sought support from doctors if they needed
additional guidance. All visited facilities stored their drugs, including oxytocin,
on shelves. Only MCWCs stored oxytocin in refrigerators.

Oxytocin stored

Most drugs (especially injectable or intravenous infusions) are administered
at room termperature
by physicians and trained service providers. Most providers have pre-service
training and on-the-job training on clinical decision making and drug administration. The interviews revealed
that, due to a lack of coordination between drug store keepers and providers, providers are unaware of
which drugs and commodities are available in facility stores. Also, many providers reported an inability to
estimate the consumption rate of drugs and commodities in their facilities because they lack data.

Private pharmacies and drug stores
Twenty-seven private drug stores and pharmacies were visited in August and September 2013 at district,
sub-district, and community levels to determine drug and commodity availability. At all private drug stores,
the most available drugs were amoxicillin, zinc, and ORS: All drug stores and pharmacies had these drugs
stocked on the day of the visit.
TABLE 2: Maternal and neonatal health drugs and commodities available in private drug stores and pharmacies, by district
District
Maternal and neonatal drug
or commodity
Oxytocin for PPH
Misoprostol for PPH
Magnesium sulphate (MgSO4) for severe
pre-eclampsia/eclampsia
Injectable antibiotics for newborn sepsis
Antenatal corticosteroids for PTRDS
Chlorhexidine for newborn cord care
Resuscitation devices for newborn
asphyxia
Amoxicillin for pneumonia
ORS for diarrhea
Zinc for diarrhea
Female condom
Contraceptive implants
Emergency contraceptive pill
N

25
26
27

They sell different dose forms
Not available
Not authorized to sell
14

Gazipur
City/
Sadar
4
3
2

Sub-district
0
2
0

Zinaidah
City/
Sub-district
Sadar
5
5
7
5
5
5

Comilla
City/
SubSadar
district
3
2
2
3
0
0

Total (%)
19 (70%)
22 (82%)
12 (44%)

3
025
025
026

2
025
025
026

7
025
025
026

5
025
025
026

3
025
025
026

3
025
025
026

23 (85%)
0 (0%)25
0 (0%)25
0 (0%)26

6
6
6
026
027
1
6

3
3
3
026
027
1
3

7
7
7
026
027
5
7

5
5
5
026
027
5
5

3
3
3
026
027
3
3

3
3
3
026
027
2
3

27 (100%)
27 (100%)
27 (100%)
0 (0%)26
0 (0%)27
17 (63%)
27

Other drugs such as oxytocin, misoprostol, and MgSO4 were
less available. Almost all drug sellers report low demand for
Oxytocin, Misoprostol, and MgSO4 and that the drugs require
a doctor’s prescription, making their sales volumes
dependent on the extent to which doctors prescribe them.
Drug store keepers explained that they lose money if drugs
expire while on their shelves due to slow sales, and thus they
do not stock them. In 15 percent of drug stores, injectable
antibiotics were not found at the day of the visit. Similarly,
ECPs were not found in 37 percent of drug stores. This
Private drug store
pattern of unavailability was similar for all city or Sadar, subdistrict, and community levels. No seasonal variations were
observed except for SMC ORSaline-N: Most drug sellers indicated that the demand for Social Marketing
Company’s ORSaline-N peaks in summer and quickly goes off the market due to increased demand. ORS
produced by other companies are available in all seasons. Dexamethasone and betamethasone and
chlorhexidine are available in all drug stores, but in different dose forms and unsuitable for pre-term
respiratory distress syndrome and newborn cord care, respectively. Resuscitation devices and female
condoms were not available in any of drug stores. MoHFW policy does not allow private drug stores to sell
contraceptive implants.
A substantial price difference was observed for all drugs according to place of manufacture, whether in
Bangladesh or overseas. Drugs manufactured overseas or by foreign companies in Bangladesh are more
expensive than those produced locally, while no significant differences in prices were observed among dugs
manufactured in Bangladesh. According to drug sellers, the price of most drugs (except injectable antibiotics)
was affordable to end users. Drug sellers were unable to rate the quality of their different products and rely
on the opinions of prescribing physicians.
Maintenance of a cold chain of storage for oxytocin’s stability is crucial, yet two out of nine drug stores in
Gazipur district, six out of 12 in Zinaidah district, and one out of six in Comilla district stored oxytocin on
shelves rather than in the refrigerators. No drug seller had a refrigerator on the premises. All other drugs
were stored on shelves at room temperature as well.

LOGISTICS AND SUPPLY ORDERING
Interviews with policymakers and program managers reveal that
centralized and decentralized procurement processes for
commodities and logistics each exist within MoHFW. MoHFW
follows the World Bank procedure for procuring drugs and
commodities, through an open bidding process, whereby the
lowest bidder is awarded the supply contract if they have the
requisite qualifications and fulfill the specifications in the tender.
Register and reporting form

Procurement is by two separate MoHFW systems. In the public
health sector, most procurement is by the Centre for Medical Store Depot, at the central level, with a few
items purchased at district levels. Drugs purchased at the district level are directed by a committee of the
Civil Surgeon, Resident Medical Officer, Gynecological and Obstretics Consultant, and Surgery Consultant
that estimates purchase volumes based on the previous year’s utilization of the individual product. Usually,
however, drugs and commodities are ordered at the national level, stored at the central warehouse, and
then distributed to districts and facilities. There is no scope for local procurement, at the sub-district level,
for health departments. All drugs and commodities are forecasted at the central level according to the lower
level facilities’ requests for each commodity.
The FP sector has an extensive process for procurement and logistics. Typically, a Director executes a need
assessment of drugs and commodities based on utilization rates, includes it in the appropriate year’s
procurement plan, and the information is loaded to the MoHFW web portal. The Ministry provides approval
for procurement and DGFP issues the tender, with a tender evaluation committee (with the Director General,
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Director of Logistics and Procurement, the respective Director, and two members from the other two
ministries) evaluating the subsequent proposals and ranking them on their technical and financial aspects.
The central warehouse mainly procures DDS Kits (Appendix 3), misoprostol, oxytocin, and contraceptives
with the exception of ECPs. A quality control team verifies and certifies the quality of each drug and
commodity according to the supply order, after which payment is made. Distribution is usually according to
forms 728 and 7b29 and calculated for estimated consumption in the coming three months. Each facility then
receives their allocated number of DDS Kits containing 26 drugs and commodities per kit. Contraceptive
forecasting and procurement occur at the central level, with storage is at the central warehouse, followed by
distribution to regional warehouses and then to upazila stores, from which facilities and workers collect
commodities. In all facilities including warehouses, at least one month’s supply of drugs and commodities
are mandated, unless there is a central shortage of a supply. Contraception and DDS Kit distribution is
usually in accordance with the ‘push’ method, permanent methods are procured ‘on demand’ by facilities. All
facilities record supply and use of drugs and commodities in registers. DGFP’s LMIS system tracks the 13 UN
commodities. SIAPS is working with DGHS to develop a similar system.
Private and NGO clinics have their own systems for commodity purchase and supply according to their
needs. Private and NGO clinics can collect contraceptives from their local authorities and, if registered with
the FP department, can provide FP services.
Most respondents in facilities were unaware of the national quality control guidelines and assurances.
Respondents from pharmaceutical companies did, however, mention that DGDA quality control guidelines
require them to have their own Standard Operating Procedures (SOPs) and ISO certifications. Service
providers in facilities mentioned that end users are not willing to pay for drugs and commodities. In addition,
they also mentioned low demand for oxytocin, misoprostol, MgSO4, ANCS, zinc, and ECP.

MANUFACTURING AND DISTRIBUTION
Several domestic pharmaceutical manufacturers produce most of the 13 life-saving commodities;
resuscitation devices, contraceptive implants, and female condoms are the only products not manufactured
locally. In this study two manufacturers were visited, and relevant persons interviewed. The two companies
visitied manufacture most of the listed drugs and commodities available in Bangladesh (Table 3b). Drugs
and commodities manufactured by local pharmaceutical companies are available at www.bddrugs.com.
Contraceptive implants (Implanon) are imported from Organon, MSD, and Netherland, and are distributed by
Janata Traders.
Resuscitation devices were donated by USAID through the Helping Babies Breathe program. Many
companies do not manufacture hormonal preparations such as contraceptive pills or injectables—only one
pharmaceutical company manufactures injectable contraceptives—but at least four companies produce
ECPs. No pharmaceutical company produces Chlorhexidine and antenatal corticosteroids in appropriate
dose forms, although they have preparations in different dose forms for other indications. Only four local
companies (Table 3b) manufacture and market oxytocin, as its need for cold chain production and storage
require more specialized resources and skills.
The prices of local products are regulated by DGDA. Without DGDA approval no pharmaceutical company can
set a price for their drugs or commodities. Companies adhere to drug policy rules and regulations when
setting their prices, which results in no excessive pricing differences for drugs produced by various domestic
companies; drugs manufactured by foreign companies do not adhere to those pricing guidelines.
Pharmaceutical companies generally teach storage practices to drug distributors but not to drug stores
themselves, which has resulted in difficient knowledge of correct product storage. Although there is no
visible public-private partnership in pharmaceutical production, DGDA has expressed an interest in such
efforts.

28
29

Monthly issue, distribution and balanced sheet, central and regional warehouse
Upazila monthly supply, distribution and stock balance report
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QUALITY CONTROL AND ASSURANCE
Bangladesh’s National Drug Policy requires each pharmaceutical
company to have quality control (QC) and quality assurance (QA) systems
for monitoring their entire manufacturing process, from acquisition of
raw materials through completion to finished product. It also requires all
pharmaceutical companies to have documented Standard Operating
Procedures (SOPs) based on WHO-recommended current Good
Manufacturing Practice guidelines for each product and unit process.
These SOPs can include quality control laboratories or access to licensed
medicine manufacturing facilities, equipment, qualified personnel,
procedures, and references30,31.
As part of the quality control program, the Bangladesh government
established two drug testing laboratories in Dhaka and Chittagong
districts. Findings from the interviews with drug authorities and
pharmaceutical representatives reveal that these drug testing laboratories’ capacities are limited both in
terms of manpower and logistics: They can only can test about 30 percent of Bangladesh’s 3,500 total
products each year.
Pharmaceutical company
Procedure Manual

Every medicine available for consumption must qualify its approved standards (specifications). The standard
for a medicine should be indicated in the application meaning which pharmacopoeia they would follow (e.g.
British Pharmacopoeia (BP), International Pharmacopeia (IP), United States Pharmacopoeia (USP), and
European Pharmacopoeia (EPh), etc.). Recently, DGDA approved the National Pharmacopoeia, which was
also approved by WHO.
As the government has limited capacity to control the quality of all drugs, it is primarily a manufacturer’s
responsibility to ensure quality, but DGDA is the National Regulatory Authority and is ultimately responsible
for the regulation and quality assurance of all medicines. Initially, licensed manufacturers develop
formulations and prepare samples of a medicine on trial and error basis in their own laboratory and test the
samples following specifications of established Pharmacopoeia. They need to validate their test procedures
and submit the samples to DGDA for testing and analysis in the Government Drug Testing Laboratory for
registration with a certificate from their own test. The submitted samples must comply with their standard
specification and passed by the Government Analyst 32.
Before confirming registration of a new product, DGDA sends a team of inspectors to assess the
pharmaceutical company’s manufacturing facility, including their drug testing laboratories. Per public drug
rules, DGDA inspects every manufacturing unit during renewal of their drug manufacturing licenses (every
two years). DGDA also monitors the quality of marketed drugs by collecting samples at random from different
drugstores and medicine markets and tests those drug samples in government laboratories. For imported
medicines all distributors should have Free Sale Certificates of the National Regulatory Authority of at least
one of the seven developed countries (UK, USA, Germany, France, Switzerland, Australia and Japan) or Good
Manufacturing Practice (GMP) certificate from WHO. This procedure is followed to ensure the safety, quality,
and effectiveness of the imported drug32.
If any drug sample is declared substandard by the government analyst then the production, distribution and
marketing of the respective batch of the drug is immediately suspended and instructions issued to the
manufacturer to withdraw the batch from all channels by publishing withdrawal notices in at least two widely
circulated daily newspapers. Simultaneously, investigations by DGDA inspectors examine the root causes.
DGDA also lodges a case in the Drug Court against the responsible persons of the drug manufacturer for
punitive actions.

30
31
32

Drug Policy of the Government of Bangladesh, MoH&FW
Quality Manual of Directorate General of Drug Administration, Bangladesh, MoH&FW
Quality Manual of Directorate General of Drug Administration, Bangladesh, MoH&FW
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PACKAGING
Findings from the in-depth interviews indicate that separate packaging of all 13 commodities is not
available. National workshop participants reiterated this fact. Many of the 13 commodities are provided in
universal dose forms, and service providers must decide how much has to be given for specific MNH
indications. Antibiotics for neonatal sepsis are available in various dose forms for drops, suspension, tablets,
and injection, each in different concentrations not specifically packaged for neonatal sepsis, but which is
simply mentioned as one of the indications on the packaging. Similarly, MgSO4 is available in solution and
power for solution forms in different concentrations. There is no separate packaging for a loading dose of 10
mg in a vial. Current available forms are 2.46 grams per 5 ml or 4 grams in per 100 ml vial, which means
that four vials are required as a loading dose in the community before referral.
All respondents in the national workshop, as well as most service providers, recommend a separate single
dose packaging of these essential drugs. They suggest the same for a single dose of gentamycin for neonatal
sepsis. The piloting of misoprostol for PPH prevention and treatment was conducted with separate packaging
specifying the indication. The same procedure is due for scale up in 18 districts. The manufacturer was
instructed to make separate packaging of 400 mcg tablets (200 mcg x 2) for PPH prevention. Similarly,
pharmaceutical companies are required to have separate package of misoprostol with mifepristone for the
specific indication of medical termination of pregnancy, and it is now on the market. No drug is included in
existing bundles such as the delivery kit but there are ongoing discussions about its inclusion. Separate
packaging had enormous support from all respondents, who feel that separate packing of appropriate doses
would greatly improve correct indications and doses.

FINANCING
It is government policy to supply all dugs and commodities (including FP commodities) free of cost to those
securing services either at facilities or through doorstep delivery31. In reality, service and drugs from facilities
are not free of cost, with clients encountering considerable out-of-pocket expenses. They frequently must
purchase drugs from private drug stores due to supply shortages or pay informal service fees33.
Clients are charged for services within the private sector. NGOs charge subsidized rates. All interviewed
respondents, workshop participants, and public facility service providers mentioned stated that end users
are not willing to pay for drugs and commodities, and the ultra poor cannot pay for anything. Drug sellers,
however, are of the opinion that, in terms of health expenditures and out-of-pocket expenses, the costs of
MNH drugs and commodities on the open market are within most end users’ reach. The respondents also
mentioned that there must be a safety net provided for the ultra poor. All respondents also felt that products
should be included in conditional cash transfer coupons, vouchers, or other similar schemes, particularly the
ongoing public sector maternal health voucher schemes.

ENGAGING POLICY MAKERS, PROGRAM MANAGERS, AND OTHER
STAKEHOLDERS
As an initial activity of this engagement, two meetings with DGFP explored how to roll out the UN Commission
recommendations. This was a follow up activity after the validation workshop that recommended forming an
advocacy forum to ensure maternal and neonatal health drug and commodities are a cause that is taken up
by relevant stakeholders. It was requested that Population Council take the responsibility for developing
Terms of Reference of the forum. DGFP’s Director of Maternal and Child Health intends to call a bigger
meeting and an effort is ongoing to create this advocacy forum.

33

Rahman, L., U. Rob, R. Mahmud, A. Alim, I.A. Hena, M.N. Talukder and H. Rahman. 2012. A pay-for-performance innovation integrating the
quantity and quality of care in maternal, newborn and child health services in Bangladesh. Dhaka: Population Council.
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Challenges, Opportunities, Recommendations
Interviews with policymakers, program managers, service providers, store keepers, drug sellers, and
workshop participants revealed a number of challenges, opportunities, and recommendations:

CHALLENGES
• Shortages of all essential drugs and commodities in public health facilities;
• Inappropriate storage of oxytocin (and consequential use of an ineffective drug during crucial medical
events) is widespread;
• Unavailability of antenatal corticosteroids in correct dose forms (6 mg injection) for pre-term respiratory
distress syndrome; unavailability of Chlorhexidine in correct concentration (7.1%) for newborn cord care;
provider use of inappropriate concentration; and lack of SDGs;
• Unavailability of Magnesium Sulfate in appropriate dose forms and need for manufacturing a single
loading dose for severe pre-eclampsia or eclampsia, and lack of interest from pharmaceutical companies;
• Lack of advocacy with pharmaceutical companies for manufacturing less profitable but essential drugs in
appropriate dose forms;
• Lack of awareness of Emergency Contraceptive Pills due to lack of educational efforts;
• Lack of knowledge and low use of zinc sulphate for neonatal diarrhea;
• Absence of a forum at DGFP that advocates for mothers and ensures access to and use of essential
maternal health drugs and commodities.

OPPORTUNITIES
• All 13 drugs and commodities are registered (except the female condom) are registered in the country in
different dose forms, meaning that registration for different, altered dose forms is feasible.
• The Directorate General of Drug Administration is very much in favor of ensuring the availability, quality,
and affordability of essential maternal and neonatal health drugs and commodities. They requested an
application for the approval of essential drugs in required dose forms. DGFP was requested to form an
advocacy forum to ensure the availability of maternal health drug and commodities. Systems for Improved
Access to Pharmaceuticals and Services (SIAPS) supported a Forecasting Working Group at DGFP. DGHS
has a Supply Chain Coordination Forum where UN, WB, UNAIDS, MoHFW, and other stakeholders are
partnered.
• Chlorhexidine has already been approved by the Directorate General of Drug Administration in appropriate
concentration, and DGHS’s National Core Committee for Neonatal Health and DGFP’s National Technical
Committee approved its use in the vertical program. Social Marketing Company has reportedly began
manufacture the drug, and Save the Children is piloting its use in one district.
• DGHS’s National Core Committee for Neonatal Health and DGFP’s National Technical Committee have
approved introduction and scale up of dexamethasone sodium sulphate 6 mg intramuscular injection for
pre-term respiratory distress syndrome, for use both in facilities and within communities.
• The Directorate General of Drug Administration issued letter for appropriate storage of oxytocin in all public
health facilities, and DGHS and DGFP have also issued letter to all facilities.
• Systems for Improved Access to Pharmaceuticals and Services (SIAPS) and other stakeholders are
facilitating DGHS’s and DGFP’s quantification of the MNH commodities needed for facilities. DGFP has an
LMIS system for tracking the 13 UN commodities. They have also proposed including Chlorhexidine and
misoprostol in standard infant delivery kits.
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• Participating respondents are concerned about the unavailability and inappropriate dose forms of MNH
commodities, suggesting a wide basis of support for improved commodity availability.
• The participating respondents are concerned about the use of low dose misoprostol for PPH prevention
and treatment.
• Social Marketing Company and Mayer Hashi of EngenderHealth initiated training for implant insertion and
removal through private providers.

RECOMMENDATIONS
Maternal health
• Misoprostol should be bundle with birthing delivery kits.
• Advocacy with pharmaceutical companies should to manufacture a single loading dose of MgSO4 solution.
• Participants have suggested assessing the effectiveness of 400 mcg versus 600 mcg misoprostol in
preventing post-partum hemorrhage in the Bangladeshi context.
• Essential drugs and commodities for mother should be made available in Union Health and Family Welfare
Centers where normal vaginal deliveries are planned and conducted.

Neonatal health
• Chlorhexidine should be bundled with birthing delivery kits.
• Resuscitation devices should be available in all districts, particularly in all facilities where deliveries are
conducted.
• Advocacy should be conducted with pharmaceutical companies to manufacture single dose of gentamycin
injection and 7.1% Chlorhexidine.
• Essential drugs and commodities for neonate should be made available in UH&FWCs where normal
vaginal deliveries are planned and conducted.
• Single dose injectable antibiotics should be manufactured and promoted for neonatal sepsis.
• Educational efforts should be strengthened toward in increasing awareness of zinc use in diarrheal
diseases.

Family Planning commodities
• DGFP should take initiatives to increase public awareness of avoiding unplanned pregnancy and ensure
availability of ECPs in all facilities as well as to fieldworkers.

General recommendations
• Formation of a forum at DGFP to advocate ensuring access to and use of MNH drugs and commodities.
• Further initiatives are necessary to ensure drug quality, appropriateness of dosage, and reliable availability
in both the private and public spheres.
• Directorate General of Drug Administration, DGFP, and DGHS should be regularly updated by active
stakeholders on the global updates on maternal and neonatal health and other public health issues.
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Table 3a: Policy, guidelines, and availability matrix of 13 life-saving maternal and neonatal health commodities in Bangladesh
Availability

Name of
commodity

Regis
tered
?

Oxytocin

Yes

Misoprostol

Yes

Magnesium
Sulphate
heptahydrate BP
(MgSO4)

Injectable
antibiotics

Injectable
antibiotics
Procaine
benzyl
penicillin

Yes

Yes

Gentamicin
sulphate

Yes

Ceftriaxone

Yes

Amoxicillin

Yes

Antenatal
corticosteroids
(ANCS)
Dexamethasone &
betamethasone41

Yes

34

Indication?

-induction
of labor
- PPHP &
treatment
- PPHP
-Anti-ulcer
-Abortive
- Various
indications

Available dose?

5 iu/1ml
ampule

Presentati
on?

Listed in
EDL?

Private/Drug
Store?

Government facility?
Natio
nal

Distric Subdi Commu Nati
t
strict
nity
onal

Commu
nity

im/iv
Injection &
Tablet

Yes

-induction of labor
- PPHP

Yes

Yes

Yes34

Yes34

No

Yes

No

Tablet

Yes

- 400 mcg for PPHP
- community
distribution by field
workers

Yes

Yes

Yes34

Yes34

No

Yes

iv/im
Injection
and
Infusion

Yes

- use in SPE/E
- piloting single
loading dose at
community

Yes

Yes

Yes34

Yes34

No

Powder
for im
Injection

Yes

- save lives due to
life threatening
infections

Yes

Yes

Yes34

Yes34

im/iv
Injection

Yes

- save lives from life
threatening
infections

Yes

Yes

Yes34

im/iv
Injection

No

- save lives due to
life threatening
infections

Yes

Yes

Drop
Susp.
iv/im
Injection
DT

Yes

- save lives due to
life threatening
infections

Yes

im/iv/tab

Yes

-used in various
indications
-recently approved
for PTRDS

No43

100 mcg
200 mcg

49.3% w/v in 5
-prevention
ml amp (2.46
and
gm)
treatment of
4% w/v in 100
SPE/E
ml iv. Solu.
Procaine
- Newborn
penicillin 3 lac
sepsis
-f Benzyl
- Various
penicillin 1
indications
lac/vial
- Newborn
20 mg
sepsis
- Various
80 mg
indications
250 mg
- Newborn
500 mg
sepsis
1 gm
- Various
indications
2 gm
100 mg/1ml
- Pneumonia 125 mg/5ml
-various
250/500
indication
mg/vial
250 mg/tab
5 mg/1 ml vial
-Various
and other
other
preparation in
indications
various dose
forms
Not available42

What is the policy?

Service
delivery
guidelin
es exist?

Storing place?

Public

In
country
manufac
turing?

Qualit
y
Qualit
assura
y
nce
contro
guideli l lab
nes
exists?
exist?

Stakeholder
interest in roll
out UN
recommendati
on?

Who can
administer?

Procure
ment?

Physician &
midwifery
nurses at
hospitals

Centrali
zed37

Yes

No

Yes

Yes38

Yes39

Interested

Private

Freeze Freeze

Able to
forecast
supply needs?
Natio Subna
nal
tional

35

36

Vary34

Shelf

Shelf

Field
workers

Centrali
zed37

Yes

No

Yes

Yes38

Yes39

Interested

Yes

No

Shelf

Shelf

Physician &
midwifery
nurses at
hospitals40

Centrali
zed37

Yes

No

Yes

Yes38

Yes39

Interested

No

Yes

Vary34

Shelf

Shelf

Physician &
trained
service
providers

Centrali
zed37

Yes

No

Yes

Yes38

Yes39

Interested

Yes34

No

Yes

Yes34

Shelf

Shelf

Centrali
zed37

Yes

No

Yes

Yes38

Yes39

Interested

Yes34

Yes34

No

Yes

Yes34

Shelf

Shelf

Centrali
zed37

Yes

No

Yes

Yes38

Yes39

Interested

Yes

Yes34

Yes34

Yes

Yes

Yes

Shelf

Shelf

Trained
service
provides

Centrali
zed37

Yes

No

Yes

Yes38

Yes39

Already in
system

Yes

Yes44

Yes44

Yes44

Yes44

Yes44

Shelf

Shelf

Trained
service
providers

Centrali
zed37

Yes

No

Yes

Yes38

Yes39

Interested

Physician &
trained
service
providers
Physician &
trained
service
providers

Some places it is available and some places not.
In most places they kept it in the shelf in normal temperature.
In most of the places they kept it in normal temperature and found in shelf.
37
Centralized procurement but if needed local level can purchase it from the local market from available fund.
38
Companies follow the QA guidelines of that pharmacopeias from where the drug is originated or the ingredients are purchased.
39
Both public and pharmaceutical have their own quality control laboratories (QC lab). GOB has two laboratories and has limited capacity and resources to check quality of all pharmaceutical products. There are 3500 pharmaceutical products. By two QC lab GOB can check only one-third products. About
30% of the pharmaceuticals have their own QC lab and they provided QC certificate to the drug administration. It is alleged that QC measures are lacking both GOB and private companies.
40
Trial is being conducted to administer loading dose of MgSO4 through community based facility level service providers
41
Injection is not available.
42
Available dose is 5mg/1ml iv or im injection
43
Available dose is 5mg/1ml are intended for various other reasons not for PTRDS. PTRDS needs 6mg im/iv dose that is not available. SDGs are being prepared.
44
Available but not in appropriate dose form. Not in injection form.
35
36
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Availability

Name of
commodity

No

Chlorhexidine

digluconate

Regis
tered
?

Indication?

- Neonatal
umbilical
cord care

7.1% not
available

-

0.16% – 0.60%

Solution

0.16% – 0.60%

Solution,
Hand rub

Eyewash

.05%

Solution

Dental wash

0.12%-1%

Solu,, gel

Preoper.
skin
cleansing

2.0%

Solution

- Newborn
asphyxia

240 ml/500 ml
size volume,
specifically
designed

Selfinflating
bag, mask
& suction
devices

Vaginal
cleansing
Neonatal
skin wiping
gluconate

Resuscitation
devices

Yes46

Yes

Available dose?

Presentati
on?

ORS48

Yes

- Diarrhea

Zinc50

Yes

- Diarrhea

Female condom

No

Contraceptive
implants
(implanon/ Jadelle)

Yes

Emergency
contraception

Yes

Nacl 1.30 gm;
Kcl 0.75 gm;
Tri Sodium
Citrate, Dye
Hydrate 1.45
gm; Glucose,
Anhydrous
6.75 gm49
Zinc sulphate
monohydrate
10 mg/20 mg/5
ml/tab/syrup
-

-long-term
68 mg
(3-5 yrs)
etonogestrel
female
75 mg
contraceptio
levonorgestrel
n

-Back-up
0.75 mg/ 1.5
contraceptio
mg/tab
n
Levonorgestrel

Sachet

Tablet

Listed in
EDL?

One rod
Two rods

Tablet

45

Private/Drug
Store?

Government facility?
Natio
nal

Distric Subdi Commu Nati
t
strict
nity
onal

Storing place?

Commu
nity

Public

Private

Who can
administer?

Procure
ment?

Able to
forecast
supply needs?
Natio Subna
nal
tional

47

53

Policy is there to make it available but there is lack of supply.

22

Qualit
y
Qualit
assura
y
nce
contro
guideli l lab
nes
exists?
exist?

Stakeholder
interest in roll
out UN
recommendati
on?

No

No45

No

No

No

No

No

No

-

-

Trained
service
providers

-

Yes

No

Planned

-

Yes39

Interested

Yes

- reduce bacterial
infection in various
situation
-over the counter

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Shelf

Shelf

Trained
service
providers

Centrali
zed37

Yes

No

Yes

Yes

Yes39

-

No

-manage newborn
asphyxia

Yes

Yes

Yes47

Yes47

No47

Yes

No

Shelf

Shelf

Trained
service
providers

Donated

Yes

No

No

No

No

Interested

Centrali
zed37

Yes

No

Yes

Yes38

Yes39

Already in
system

Over the
counter
product

Yes

-rehydration
therapy for
diarrhea
- over the counter

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Shelf

Shelf

Yes

-prevent diarrhea
-feed for 10 days
- over the counter

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Shelf

Shelf

Over the
counter
product

Centrali
zed37

Yes

No

Yes

Yes38

Yes39

Already in
system

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Yes

Yes

Yes

Yes

No51

No52

No

Shelf

Shelf

Yes

No

No

No

No

Already in
system

Yes

Yes

Yes53

Yes53

Yes53

Yes

Yes

Shelf

Shelf

Yes

No

Yes

Yes38

Yes39

Already in
system

-

Not interested
-On-demand
In the
-Available at
method designated facility
mix
-any woman eligible
even nulliparous
- over the counter
DGFP
-single dose within
method
5 days of
mix
unprotected sex

Only trained Centrali
Physician
zed
Over the
counter
product

Centrali
zed

One piloting is being conducted and working with MOH for the preparation and guidelines for the required concentration (7.1% chlorhexidine digluconate for cord cleansing).
The ingredient is registered but the concentration required for newborn cord care is not available or registered. Various concentration and combination is available. They are all Chlorhexidine gluconate and hydrochloride not Chlorhexidine digluconate.
Only in district where HBB program was implemented. In most of the places it is not available.
48
Also available with supplements
49
WHO & UNICEF new formulae for ORS
50 Also available with supplements
51
In most places not available but in some places available where primary level facilities are upgraded or camps are being organized.
52
In a very few places it available with NGO initiatives.
46

In
country
manufac
turing?

-recently approved
for newborn cord
care at facility and
community
-single use during
umbilical cord
stamp followed by
dry cord care

Syrup
-

What is the policy?

Service
delivery
guidelin
es exist?

Table 3b: Availability matrix of 13 life-saving maternal and neonatal health commodities in Bangladesh, by pharmaceutical companies,
market retail price, available packaging, and willingness to pay by end users
Name of commodity

Name of pharmaceutical companies who manufacture it

Brand names

Available dose?

Market prices?

Separate
packaging?

WTP by
end-user?

Oxytocin

Nuvista Phar. Ltd., Opsonin Phar. Ltd., Chemist Laboratories Ltd., Techno
Drugs

Linda-S, Ocin, Pitocin, Syntocin

5 iu/1ml ampule

Tk.54 8-11/amp

No

Yes55

Tk..8/tab
Tk.10-15/tab

Yes57

Yes55

Eclamsil 49.3%, G-Magsulph 49.3%,
Magsum 49.3%

100 mcg
200 mcg
49.3% w/v in 5ml amp (2.46
gm)

No

Yes55

G-Magsulph 4%, Nalepsin 4%

4% w/v in 100 ml iv. solution

No

Yes55

No

Yes55

No

Yes55

Yes

Yes

Yes

Yes55

Misoprostol 56

Incepta Phar. Ltd., Gonoshasthaya Phar. Ltd., Square Phar. Ltd.

Magnesium Sulphate heptahydrate BP
(MgSO4)

Opsonin Phar. Ltd, Gonoshasthaya Phar. Ltd (GPL), Renata Ltd, Gonoshasthaya Phar.
Ltd (GPL), Beximco Phar. Ltd.

Cytomis, G-Misoprostol, Isovent

Injectable antibiotics
Combipen 4 Lac, Pronapen 4 Lac
Procaine benzyl penicillin

ACME Laboratories Ltd, Renata Ltd

Injectable antibiotics

Pronapen 8 Lac
Gentamicin
sulphate

Ceftriaxone

Amoxicillin

Renata Ltd., Techno Drugs, IBN SINA Phar. Industry Ltd., Aristopharma Ltd., Beximco
Ceftizone, Cefixon, Axosin, Axon, Arixon,
Phar. Ltd., ACI Ltd, Novo Healthcare and Phar. Ltd., Square Phar. Ltd., Drug
Aciphin, Ceftrix, Ceftron, Dicephin,
International Ltd., Sanofi-aventis (Bd) Ltd., Popular Phar. Ltd., Incepta Phar. Ltd., GPL,
Enocef, Eracef, Exephin, G-Ceftriax,
General Phar. Ltd., Rephco Laboratories Ltd., Apex Phar. Ltd., Sandoz/Novartis (Bd)
Imacef, Inoxon, Keptrk, Megion, Oricef,
Ltd., Healthcare Phar. Ltd, Rangs Phar. Ltd., Jayson Phar. Ltd., Kemiko Phar. Ltd.,
Oryx, Parcef, Rit, Rofecin, Topcef, Trax,
Radiant Phar. Ltd., Navana Phar. Ltd., Medimet Phar. Ltd., Opsonin Phar. Ltd, Globe
Traxon, Tribac, Triject, Triphin, Trizon,
Phar. Ltd., Eskayef (Bd) Ltd., Ziska Phar. Ltd., ACME Laboratories Ltd., Orion Phar.
Vertex, Winner, Xylib
Ltd., Bio-pharma Laboratories Ltd., Libra Phar. Ltd.
Square Phar. Ltd.

Moxacil DT

Injection

Opsonin Phar. Ltd, Renata Ltd., Jayson Phar. Ltd., ACI Ltd., Drug International Ltd.,
Gonoshasthya Phar. Ltd., Square Phar. Ltd., Acme Laboratories Ltd., Techno Drugs,
Gaco Phar. Ltd.

Amoxi, Amoxon, Avlomox, Demoxil, GAmoxycillin, Moxaci, Moxilin, Moxin,
Penmox, Unimox

Suspension

Capsule

Tablet

Aexim Phar. Ltd., Ambee Phar. Ltd., Sonear Laboratories Ltd., Syntho Laboratories
Almoxil, Ambeexin, Amocap, Amocil,
Ltd., Pacific Phar. Ltd., Bio Phar. Laboratories Ltd., Doctor’s Chemicals Works Ltd.,
Amocin, Amotid, Amotid, Amox, Amoxi,
Renata Ltd., Cosmo Phar. Laboratories Ltd., Medicon Laboratories Ltd., Glaxo Smith
Amoxic, Amoxicap, Amoxicon, Amoxil,
Kline (Bd) Ltd, Modern Phar. Ltd., Salton Phar. Ltd., Zenith Phar. Ltd., Jayson Phar.
Amoxima, Amoxipan, Amoxizen,
Ltd., Rangs Phar. Ltd., Apollo Phar. Laboratories Ltd., Apex Phar. Ltd , Aristopharma
Amoxon, Antif, Apimox, Apoxy,
Ltd., ACI Ltd., Benham Phar. Ltd., Bristol Phar. Ltd., Cosmic Chemical Industries Ltd., Aristomox, Avlomox, Bactamox, Benoxil,
Kumudini Phar. Ltd., Desh Phar. Ltd., Drug International Ltd., Hallmark Phar. Ltd.,
Bpmox, Brodamox, Clamox, Demox,
Elixir Phar. Ltd., Edruc Ltd., Popular Phar. Ltd., Sanofi-Aventis (Bd) Ltd., GPL, General Demoxil, Dopen, Elimox, E-Mox, Fimox,
Phar. Ltd., Millat Phar. Ltd., Medimet Phar. Ltd., Hudson Phar. Ltd., Ad-din Phar. Ltd.,
Fimoxyl, G-Amoxycillin, Genamox,
Kemiko Phar. Ltd., Asiatic Laboratories Ltd., Belsen Phar. Ltd., Amico Laboratories
Hectamox, Hiconcil, Hi-Mox, J-Mox,
Ltd., Central Phar. Ltd., Proteety Phar. Ltd., Decent Phar. Ltd., Square Phar. Ltd., Nipa
Kamoxy, Loxyl, Moci, Monamox,
Phar. Ltd., Marksman Phar. Ltd., Supreme Phar. Ltd., Acme Laboratories Ltd., Opsonin Cemoxin, Mox, Moxa, Moxacil, Moxapen,
Phar. Ltd, Shamsul Alamin Phar. Ltd., Mystic Phar. Ltd., Navana Phar. Ltd., Orion
Moxatid, Moxico, Moxilin, Moxin ,Mox,
Laboratories Ltd., Peoples Phar. Ltd., Globex Phar. Ltd., APC Phar. Ltd., Techno
Mumox, Mymoxcil, Navamox, Orixyl,
Drugs, Pharmadesh Laboratories Ltd., Reman Drug Laboratories Ltd., Rasa Phar. Ltd.,
Pamoxil, Panoxyl, Pemox, Penmox,
Rephco Laboratories Ltd., Alco Phar. Ltd., Seema Phar. Ltd., Silva Phar. Ltd., Ibn Sina
Pharmoxyl, Remamox, Roxyl, Remoxin,

1 US$=80 Taka or 1 taka=US$ 0.013
If not available in the government system people purchase. But needs “safety net”.
Pharmaceuticals branded it as anti-ulcerant, in combination with anti-inflammatory drugs, in combination with mifepristone for medial MR
57
Also for medical termination of pregnancy in combination with mifepristone.
55
56
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Egen, Genacyn, Genacyn, Gentabac,
Gentasol, Gentin, G-Gentamicin,
Intamycin, Invigen

Amoxicillin
Dispersible tablet (DT)

Drop

54

Edruc Ltd, Square Phar. Ltd., Square Phar. Ltd., Popular Phar. Ltd., Techno Drugs,
Opsonin Phar. Ltd, GPL, Incepta Phar. Ltd., Beximco Phar. Ltd., Aristopharma Ltd.

(Procaine penicillin 3 lac -f
Benzyl penicillin 1 lac/vial)
(1g =1 million IU)
(50 mg/kg IM)
Procaine penicillin 6 lac,
Benzyl penicillin 2 lac (total 8
lac) in 1 vial
20 mg
80 mg
80 mg iv infusion
250 mg iv/im
500 mg iv/im
1 gm iv/im
2 gm iv/im

Tk. 20-25/5ml amp
Tk. 55-71/100 ml
bot.
Tk. 6-10/vial

Tk. 10/vial
Tk. 6-7/2 ml amp
Tk. 9.50-12/2 ml
amp
Tk. 48/100 ml vial
Tk. 75-130/vial
Tk. 120-145/vial
Tk. 160-195/vial
Tk. 250-350/vial

im injections are almost same. In some cases it is
Tk. 20-25 less
250 mg/DT
250 mg/vial (iv/im)
500 mg/vial (iv/im)
1000 mg/vial (iv/im)
100 mg/1ml
125 mg/1.25 ml
125 mg/5ml
250 mg/5ml

Tk. 3.50/DT tab.
Tk. 18-22/vial
Tk. 21-27/vial
Tk. 46/vial
Tk. 27-31/15 ml bot.
Tk. 27-31/15 ml bot.
Tk. 40-55/100 ml
bot.
Tk. 60-68/100 ml
bot.

250 mg/cap

Tk. 2.50-3.50/cap

500 mg/cap

Tk. 4.50-6.50/cap

250 mg/tab

Tk. 3.5-4.0/tab

875 mg/tablet

Tk. 8.50-10.00/tab

Antenatal
corticosteroids
(ANCS)

Name of commodity

Dexamethasone sodium phosphate

Name of pharmaceutical companies who manufacture it

Brand names

Phar. Ind. Ltd., Eskayef (Bd) Ltd., Skylab Ltd., Beximco Phar. Ltd., Somatec Phar. Ltd.,
Globe Phar. Ltd., Gaco Phar. Ltd., Ziska Phar. Ltd.

Sapox, Seemaxyl, Simox, Sinamox, Sk-Mox
, Skymoxin, Tycil, Tymox, Ultramox,
Unimox, Zimoxyl

Could manufacture by all pharmaceuticals below

-

Globe Phar. Ltd., Techno Drugs, Opsonin Phar. Ltd, Renata Ltd., Medimet Phar. Ltd., D-Cort, Decafos, Decason, Dexa, Dexam,
Rephco Laboratories Ltd., Globe Phar. Ltd., Techno Drugs, Renata Ltd., Medimet
Dexamet, D-Cort, Decafos, Decason,
Phar. Ltd., Rephco Laboratories Ltd., Jayson Phar. Ltd., Chemist Laboratories Ltd., Ibn Dexa, Dexam, Dexamet, Dexamin, Dexan,
Sina Phar. Industries Ltd., Ziska Phar. Ltd., Gonoshasthya Phar. Ltd., Gaco Phar. Ltd.,
Dexon, Dextason, G-Dexamethasone,
Nuvista Phar. Ltd., Aristopharma Ltd.
Meradexon, Oradexon, Sonexa

Betamethasone59 sodium phosphate

Manufacture by a number of pharmaceuticals but different preparation no injection

-

Digluconate

Not manufacture by any pharmaceuticals

-

Gonoshasthaya Phar. Ltd, Square Phar. Ltd., Eskayef Bangladesh Ltd., ACI Ltd,
Opsonin Phar. Ltd, Silva Phar. Ltd, Silva Phar. Ltd, Medimet Phar. Ltd., Aristopharma
Ltd.

G-Antiseptic, Germisol, Handirub,
Hexiscrub, Hexisol, Kevirub, Safetisol,
Safetisol, Safwash, Xisol, Oralon, Oralon
Dental

Resuscitation devices

NA

-

ORS60

SMC

ORSaline-N, ORS Fruti, Tasti saline

Hand Rub

Gluconate

Chlorhexidine

Solution

Hand Rub
Solution (Mouth Wash)
Solution

Zinc62
Sulphate monohydrate

Female condom
Contraceptive implants
(Implanon/Jadelle)
Emergency contraception

58

Available dose is 5mg/1ml iv or im injection
Injection is not available.
Also available with supplements
61
WHO & UNICEF new formulae for ORS
62 Also available with supplements such as vitamins
59
60
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Acme Laboratories Ltd., Pacific Phar. Ltd., Bristol Phar. Ltd., Benham Phar. Ltd., CPL,
Baby Zinc, Bimuty, Bimuty, Bp Zinc, B-Zn,
ACI Ltd., Elixir Phar. Ltd., Eskayef Bangladesh Ltd., Edruc Ltd, GPL, Ibn Sina Ltd., AdC-Zinc, Dispazinc, E-Zinc, Ezy Xinc,
din Phar. Ltd., Gaco Phar., Renata Ltd, Opsonin Phar. Ltd, NOVO Healthcare and
Grow, G-Zinc, Inate, J-Zinc, Kids-B, Mazic,
Phar. Ltd., Aristopharma Ltd., Navana Phar. Ltd., Supreme Phar, Proteety Phar. Ltd.,
Nid, Novo Zinc, Oral-Z, Oralzin, Orazinc,
Orion Phar. Ltd., Nipa Phar. Ltd., Rasa Phar. Ltd., Popular Phar. Ltd., Pharmadesh
Pedi-Z, Pem Ds, Pep-2, Peptin, Rozinc,
Laboratories Ltd., Pharmacia Pvt. Ltd., Jayson Phar. Ltd., Beximco Phar. Ltd., Hudson
Soluzinc, Syrup Zinc, Syrup-Zp, Tiny-Z,
Phar. Ltd., Chemist Laboratories Ltd., Cosmic Phar. Pvt Ltd., Alco Phar. Ltd., Square
Xinc, Z-Dt, Zeal, Zedex, Zee-2, Zeenee,
Phar. Ltd., General Phar. Ltd., Incepta Phar. Ltd., Globe Phar. Ltd., Zenith Phar. Ltd,
Zeenk, Zep, Zesup, Zico, Zido, Ziflu,
Apollo Phar. Laboratories Ltd., Desh Phar. (Pvt.) Ltd., Somatec Phar. Ltd., Ziska Phar.
Zikid, Zimon, Zinca, Zincep, Zincol,
Ltd., Ambee Phar. Ltd., Bikalpa Phar. Ltd., Bio Phar. Laboratories Ltd., Modern Phar.
Zincoral, Zinc-S, Zincsy, Zinga, Zinofa,
Ltd., Medicon Laboratories Ltd., Kumudini Phar. Ltd., Rephco Laboratories Ltd., Apex
Zinon, Zinpro, Zinup, Zipol, Zis Ds,
Phar. Ltd., Acme Laboratories Ltd., Chemico Laboratories Ltd., Marksman Phar. Ltd.,
Zismo, Zisul, Zisulmet, Ziton, Zixol,
Medimet Phar. Ltd, Drug International Ltd., Unimed & Unihealth Manufacturers Ltd.,
Znkid, Zs, Z-Sil Dt, Z-Sil, Zym
Delta Phar. Ltd, Decent Phar. Laboratories Ltd., Silva Phar. Ltd., Hallmark Phar. Ltd.,
Not available
Implanon imported from Organon. Marketed by MSD and local distributor is Janata
Implanon
Traders
Jadelle imported from Bayer Schering Phar. AG
(I-plant)
Imported from Gedeon Richter (City Overseas), and Renata Ltd., SMC,
Postinor-2, Emcon, Norix, Norpil 1
Square Phama. Ld.

Available dose?

Market prices?

Separate
packaging?

WTP by
end-user?

5 mg/1ml amp but 6 mg/12
mg/1ml amp not available58

-

-

-

5 mg/1 ml amp

Tk. 9-22/amp

No

Yes55

-

No

Ointment, drop, cream, tablet
(Glaxo)
7.1% aqueous solution

No
Tk. 16-31/100 ml
BP solution
bot.
Chlorhexidine gluconate 0.5% Tk. 24-31/50 ml bot.
w/w in 70% Isopropanol
Tk. 80-105/250 ml
solutions
bot.
No
Chlorhexidine gluconate 0.5%
Tk. 30/50 ml bot Tk.
w/v in Isopropyl alcohol 20%
80/200 ml bot
w/v solution
0.2% w/v solution
Tk. 35/100 ml bot.
4% solution
Tk. 100/250 ml bot.
240 ml/500 ml size volume,
NA
Not needed
specifically designed
Sodium Chloride 1.30 gm;
Potassium Chloride 0.75 gm;
Tri Sodium Citrate, Dye
Tk. 4.5-6.0/pack
Not needed
Hydrate 1.45 gm; Glucose,
61
Anhydrous 6.75 gm
20 mg/tab

Tk. 1.5-2.0/20 mg
tab

10 mg/5ml syrup

Tk. 25-30/100 ml
bot.

20 mg/5ml syrup

Tk. 50-55/100 ml
bot.

-

-

68 mg etonogestrel/rod

$ 8.5-10/implant

75 mg levonorgestrel/rod
0.75 mg/1.5 mg of
Levonorgestrel/tab

$ 8.0-10/two stick
Tk. 30-45/two tab

Yes55

Yes55

No

Yes55

Not needed

Yes55

-

-

Yes

No

Yes

Yes55

Appendix 1: Bangladesh Essential Drugs List
LIST OF ESSENTIAL DRUGS
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Sl.
1
2
3
4
5
6
7

Name of drugs
Abacavir (ABC)
Acetazolamide
Acetylsalicylic acid
Aciclovir
Albendazole
Allopurinol
Aluminium hydroxide + Magnesium hydroxide

8
9
10

Amitriptyline
Amlodipine Besylate
Amoxicillin

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

Ampicillin
Anti-D immunoglobulin (human)
Antitetanus immunoglobulin (human)
Artemether + Lumefantrine*
Artesunate
Ascorbic Acid
Atenolol
Atropine
Barium Sulfate
BCG vaccine
Benzathine benzylpenicillin
Benzoic acid + Salicylic acid
Benzyl benzoate
Benzyl penicillin
Betamethasone
Bleomycin
Bupivacaine
Calcium gluconate
Carbamazepine
Charcoal, activated
Chlorambucil
Chloramphenicol
Chlorhexidine
Chloroquine
Chlorpheniramine
Chlorpromazine
Ciprofloxacin
Cisplatin
Clofazimine
Clotrimazole
Cloxacillin
Condoms
Cyclophosphamide
Dapsone
Dexamethasone
Dextran 70
Diazepam
Didanosine (ddl)

49
50
51
52
53
54

Diethylcarbamazine
Digoxin
Diloxanide
Diphtheria antitoxin
Diptheria vaccine
Dopamine

Dosage form
Oral Liquid, Tablet
Tablet
Suppository, Tablet
Powder for injection, Tablet
Tablet (chewable)
Tablet
Oral liquid, Tablet
Tablet
Tablet
Capsule or Tablet, Powder for oral liquid, Powder for
injection
Powder for Injection
Injection
Injection
Tablet
Injection, Tablet
Tablet
Tablet
Injection, Solution (eye drops)
Aqueous suspension
Injection
Powder for injection
Ointment or cream
Lotion
Powder for injection
Ointment or cream
Powder for injection
Injection
Injection
Oral liquid, Tablet (chewable), Tablet (scored)
Powder
Tablet
Eye drops, Eye ointment
Solution
Oral liquid, Tablet
Injection , Tablet
Injection, Oral liquid, Tablet
Tablet or powder for suspension
Injection
Capsule
Vaginal cream, Vaginal tablet
Capsule, Powder for injection, Power for oral liquid,
Powder for injection, Tablet
Tablet
Injection
Injectable solution
Injection, Tablet, Tablet (scored)
Buffered powder for oral liquid, Capsule (unbuffered enteric
coated), Tablet (buffered chewable, dispersible)
Tablet
Injection, Oral liquid, Tablet
Tablet
Injection
Injection
Injection
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55
56
57
58
59
60
61
62
63

Doxorubicin
Doxycycline
DPT vaccine
Efavirenz (EFV or EFZ)
Enalapril
Epinephrine (adrenaline)
Ergocalciferol
Ergometrine
Erythromycin

64
65
66
67
68
69
70
71
72
73

Ethambutol
Ethinylestradiol + Levonorgestrel
Ferrous salt
Ferrous salt + Folic acid
Fluconazole
Fluorescein
Fluorouracil
Fluphenazine
Folic acid
Furosemide

Powder for injection
Capsule or Tablet, Tablet (dispersible)
Oral + Injection
Capsule, Oral liquid, Tablet
Tablet
Injection, Solution (eye drops)
Capsule or Tablet, Oral liquid
Injection
Capsule or Tablet, Powder for injection, Powder for oral
liquid
Tablet
Tablet
Oral liquid, Tablet
Capsule, Tablet
Capsule, Oral liquid
Eye drops
Injection, Ointment
Injection
Tablet
Injection, Tablet

74
75
76
77
78
79
80
81
82
83
84
85
86

Gentamycin
Gentamycin + Hydrocortisone
Glibenclamide
Gliclazide
Glucose
Glucose with sodium chloride
Glyceryl trinitrate
Griseofulvin
Haloperidol
Halothane
Heparin sodium
Hepatitis B vaccine
Homatropine

Injection, Solution (eye drops)
Ear drop
Tablet
Tablet
Injectable solution
Injectable solution
Tablet (sublingual)
Capsule or Tablet
Injection, Tablet
Inhalation
Injection
Injection
Solution (eye drops)

87
88
89

Human normal immunoglobulin
Hydrochlorothiazide
Hydrocortisone

Intramuscular administration, Intravenous administration
Tablet (scored)
Powder for injection, Ointment or cream, Suppository

90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112

Hyoscine butylbromide
Ibuprofen
Indinavir (IDV)
Insulin Injection (Soluble)
Isoniazide
Isoniazide + Ethambutol
Isosorbide dinitrate
Ketamine
Lamivudine (3TC)
Levamisole
Levodopa + Carbidopa
Levothyroxine
Lidocaine
Lithium Carbonate
Lopinavir + Ritonavir (LPV/r)
Magnesium hydroxide
Magnesium sulfate*
Mannitol
Measles vaccine
Mebendazole
Mefloquine
Metformin
Methotrexate

Tablet, Injection
Tablet
Capsule
Injection
Tablet, Tablet (scored)
Tablet
Tablet (sublingual)
Injection
Oral liquid, Tablet,
Tablet
Tablet
Tablet
Injection, Topical
Capsule or tablet
Capsule, Oral liquid
Oral liquid
Injection
Injectable solution
Injection
Tablet (chewable)
Tablet
Tablet
Powder for injection, Tablet
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113
114

Methyldopa
Methylrosanilinium chloride (gentian violet)

Tablet : 250 mg
Aqueous solution, Tincture

115
116
117
118
119
120

Metoclopramide
Metronidazole
Miconazole
Miltefosine
Misoprostol
Morphine

Injection, Tablet
Injection, Oral liquid, Suppository, Tablet
Ointment/Ceam
Capsule/Oral liquid
Tablet
Injection, Oral liquid, Tablet, Tablet (prolonged release)

121
122
123
124
125
126
127
128
129
130
131

Naloxone
Nelfinavir (NFV)
Neomycin Sulfate + Bacitracin
Neostigmine
Nevirapine (NVP)
Nicotinamide
Nifedipine
Nitrofurantoin
Nitrous oxide
Nystatin
Omeprazole

Injection
Oral powder, Tablet
Ointment
Injection, Tablet
Oral liquid, Tablet
Tablet
Immediate release capsule
Tablet
Inhalation
Oral Suspension
Capsule

132
133
134
135
136
137
138

Oral rehydration salts
Oseltamivir
Oxygen
Oxytocin
Paracetamol
Paromomycin
Peritoneal Dialysis Solution

Powder
Tablet
Inhalation
Injection
Oral liquid, Suppository, Tablet
Solution for intramuscular injection
Intraperitoneal dialysis solution (of appropriate composition)

139
140
141

Permethrin
Pertussis vaccine
Pethidine hydrochloride

Cream, Lotion
Injection
Injection

142
143
144

Phenobarbital
Phenoxymethylpenicillin
Phenytoin

Injection, Oral liquid, Tablet
Powder for oral liquid, Tablet,
Capsule, Injection, Oral liquid, Tablet, Tablet (chewable)

145
146

Pilocarpine
Poliomyelitis vaccine

Solution (eye drops)
Oral

147

Polyvalent anti snake venom

Injection

148
149
150
151
152
153
154
155
156
157
158
159

Potassium chloride
Povidone Iodine
Prednisolone
Primaquine
Procainamide
Procaine benzylpenicllin
Procarbazine
Proguanil
Promethazine
Propranolol
Protamine sulfate
Pyrazinamide

Tablet, Solution
Solution
Tablet, Solution (eye drops)
Tablet
Injection
Powder for injection
Capsule
Tablet
Oral liquid, Injection, Oral liquid, Tablet
Tablet
Injection
Tablet, Tablet (dispersible), Tablet (scored)

160
161
162
163
164
165

Pyridoxine
Pyrimethamine
Quinine
Rabies immunoglobulin
Rabies vaccine
Retinol

Tablet
Tablet
Injection, Tablet
Injection
Injection
Capsule, Tablet, Oral oily solution, Water-miscible injection

166
167

Riboflavin
Rifampicin

Tablet
Capsule or Tablet

168
169

Rifampicin + Isoniazid
Rifampicin + Isoniazid + Ethambutol

Tablet
Tablet

170
171

Rifampicin + Isoniazid + Pyrazinamide
Rifampicin + Isoniazid + Pyrazinamide + Ethambutol

Tablet
Tablet

172

Ritonavir

Oral liquid, Oral solid dosage form

173

Salbutamol

174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198

Salicylic acid
Saquinavir (SQV)
Senna
Silver sulfadiazine
Sodium chloride
Sodium Chloride 3%
Sodium Chloride quartet strength (0.225%) +
Dextrose 5%
Sodium Hydrogen Carbonate
Sodium stibogluconate
Sodium thiosulfate
Spironolactone
Stavudine (d4t)
Streptomycin
Sulfadoxine + Pyrimethamine
Sulfamethoxazole + Trimethoprim
Suxamethonium
Tamoxifen
Tenofovir disoproxil fumarate (TDF)
Tetanus vaccine
Tetracycline
Thiamine
Thiopental
Trimethoprim
Tropicamide
Tuberculin, purified protein derivative (PPD)

Injection, Oral liquid, Respirator solution for use in nebulizers,
Tablet
Solution
Capsule
Tablet
Cream
Injectable solution
I/V fluid
I/V fluid

199

Valproic acid

Oral liquid, Tablet (crushable), Tablet (enteric coated)

200
201
202
203
204

Injection
Injection, Tablet
Powder for injection
Powder for injection
Tablet

205
206
207
208

Vecuronium
Verapamil
Vinblastine
Vincristine
Vitamin B-Complex (Vitamin B1- 5 mg + Vitamin B22 mg + Vitamin B6 - 2 mg + Nicotinamide 20 mg)
Warfarin
Water for Injection
Xylometazoline Hydrochloride
Zidovudine (ZDV or AZT)

209

Zinc sulphate

Oral liquid, Tablet

N.B: Shaded items are the drugs in the 13 life-saving commodities
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Injectable solution, Soution
Injection
Solution
Tablet
Capsule, Powder for oral liquid
Powder for injection
Tablet
Oral liquid, Tablet, Injection
Injection, Powder for injection
Tablet
Tablet
Injection
Eye ointment
Tablet
Powder for injection
Tablet
Eye drops
Injection

Tablet
Ampoule
Nasal drops
Capsule, Oral liquid, Solution for IV infusion injection, Tablet

Appendix 2: Contents of Drug and Dietary Supply (DDS) Kits
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